Argentina: Need for new test data legislation

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Argentina: Need for new test data legislation

Taking into account the benefits of test data protection, several Latin American countries have integrated proper data protection measures into their national legislation.

During the negotiations over Article 39.3 of the TRIPs Agreement, such long-term benefits to the health of the citizens of all member countries of the World Trade Organization that would result from adequate test data protection enforced by governments were expressly recognised.

As an example of such benefits we can mention that in developed countries (for example, in the United States) the data protection rights and marketing exclusivity granted by the Orphan Drug Act have resulted in a dramatic increase in the number of orphan drugs available to the public.

In the case of developing countries a serious problem is the lack of pharmaceutical products used to treat conditions or diseases that are not normally found in developed countries or when a disease affects only a reduced group of patients in developed countries, but a large number in developing countries. In this situation, the potential markets in developed countries would not always be enough to encourage the spending required for research and testing of such medicines.

Adequate test data protection in both developed and developing countries will create the proper incentives through the creation of a larger market of consumers.

Argentina

Notwithstanding these benefits, Argentina's legislation (Law 24,766 – the Confidentiality Law, Executive Order 150/92) fails to provide effective protection against unfair commercial use or unauthorised disclosure of test and other data generated to obtain marketing approval for pharmaceutical products.

The enactment of new legislation consistent with the TRIPs Agreement would improve the health and standard of living as new and better medications would be available to the general population.

zuccherino.jpg

Daniel R Zuccherino


Obligado & CiaParaguay 610, 17th FloorC1057AAH, Buenos Aires, ArgentinaTel: +54 11 4114 1100Fax: +54 11 4311 5675admin@obligado.com.arwww.obligado.com

more from across site and SHARED ros bottom lb

More from across our site

Former in-house counsel Andriana Shultz Daly has returned to the firm with client-side insight and courtroom skills to build the firm’s life sciences practice
The LMG Life Sciences Awards announces the 2025 winners for the 13th annual awards!
News of AI company Cerence accusing Apple of patent infringement and a hiring update from Lewis Silkin were also among the top talking points
The addition of BH EVS as a licensee enhances the outreach of the Qi pool, which now licenses nearly half of the global auto supplier market
Only a few international law firms have made a mark in Australia’s IP market, but Rouse entering the field could be a sign of changing times
Caroline Casalonga reflects on her journey as the French firm’s first female leader and shares her dream of building the outfit into a major European independent IP practice
Firm says the hire of Laura Ramsay will help consolidate its position as a ‘market leader’ for premium IP work
CEO Martyn Fish reflects on the past as HGF celebrates its 30th anniversary and discusses how PE investment has helped the firm’s people and clients
The 105-year-old IP firm Wrays and related business Aperture Insight will join Rouse but operate independently
The winners will be revealed during a ceremony in Ho Chi Minh City, Vietnam, on November 6
Gift this article